Project UpdateAug 10, 2026, 08:04 AM
Telomir-Zn Suppresses Cancer Growth in Preclinical Study
AI Summary
Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study in the Journal of Oncology Research and Therapy. The study demonstrated that Telomir-Zn suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models by inhibiting histone demethylases (KDMs) through intracellular iron depletion. Key findings include the reactivation of silenced tumor-suppressor genes, significant reduction in metastatic dissemination, and synergistic effects when combined with paclitaxel. These preclinical results provide a scientific foundation for advancing Telomir-Zn towards a planned Phase 1/2 clinical trial in TNBC.
Key Highlights
- Telomir-Zn inhibits JmjC Histone Demethylases (KDMs) by depleting intracellular iron.
- The compound suppressed tumor growth in prostate and triple-negative breast cancer (TNBC) models.
- Iron-rescue experiments confirmed the iron-dependent mechanism of action.
- Telomir-Zn reactivated silenced tumor-suppressor genes in a prostate cancer model.
- It significantly reduced metastatic dissemination in an HCC1806 TNBC model.
- Combination with paclitaxel showed synergistic tumor reduction in BT-549 TNBC xenografts.
- Telomir-Zn selectively targeted cancer cells, sparing normal cells at 50x higher concentrations.
Price Impact
More from TELO